Evaluation of the physicians' approach to the diagnosis and treatment of patients with antituberculosis drug-induced hepatotoxicity

Journal of Evaluation in Clinical Practice

Volumn 18, Issue 6, 2012, Pages 1119-1125

  Thongraung, Wilawan ^a   Sittidach, Maneerat ^b   Khwansuwan, Panatda ^a   Sariyasuntorn, Kanitha ^a   Wongsampan, Sirinart ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b Songklanagarind Hospital   (Thailand)

Author keywords

compliance; hepatotoxicity; management; physician; tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTITUBERCULOSIS DRUG INDUCED HEPATOTOXICITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DRUG WITHDRAWAL; HUMAN; OUTPATIENT CARE; PATIENT COMPLIANCE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TOXIC HEPATITIS; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG-INDUCED LIVER INJURY; FEMALE; GUIDELINE ADHERENCE; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; THAILAND;

EID: 84868212207     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2011.01706.x     Document Type: Article

References (28)

1. World Health Organization (2010) Global Tuberculosis Control: WHO Report 2010 WHO/HTM/TB/2010.7. Geneva: WHO Press.
2. World Health Organization (2009) Treatment of Tuberculosis: Guidelines-4th Edn. WHO/ HTM/TB/2009.420. Geneva: WHO Press.
3. Gülbay, B. E., Gürkan, O. U., Yildiz, O. A., Onen, Z. P., Erkekol, F. O., BaççioÄlu, A., &, Acican, T., (2006) Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respiratory Medicine, 100 (10), 1834-1842.
4. Døssing, M., Wilcke, J. T., Askgaard, D. S., &, Nybo, B., (1996) Liver injury during antituberculosis treatment: an 11-year study. Tubercle and Lung Disease, 77 (4), 335-340.
5. Teleman, M. D., Chee, C. B., Earnest, A., &, Wang, Y. T., (2002) Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. International Journal of Tuberculosis and Lung Disease, 6 (8), 699-705.
6. Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., &, Menzies, D., (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. American Journal of Respiratory and Critical Care Medicine, 167 (11), 1472-1477.
7. Fernández-Villar, A., Sopeña, B., Fernández-Villar, J., Vázquez-Gallardo, R., Ulloa, F., Leiro, V., Mosteiro, M., &, Piñeiro, L., (2004) The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. International Journal of Tuberculosis and Lung Disease, 8 (12), 1499-1505.
8. Marra, F., Marra, C. A., Bruchet, N., Richardson, K., Moadebi, S., Elwood, R. K., &, Fitzgerald, J. M., (2007) Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. International Journal of Tuberculosis and Lung Disease, 11 (8), 868-875.
9. Durand, F., Jebrak, G., Pessayre, D., Fournier, M., &, Bernuau, J., (1996) Hepatotoxicity of antitubercular treatments rationale for monitoring liver status. Drug Safety, 15 (6), 394-405.
10. Younossian, A. B., Rochat, T., Ketterer, J. P., Wacker, J., &, Janssens, J. P., (2005) High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. The European Respiratory Journal, 26 (3), 462-464.
11. Steele, M. A., Burk, R. F., &, DesPrez, R. M., (1991) Toxic hepatitis with isoniazid and rifampicin. A meta-analysis. Chest, 99 (4), 465-471.
12. Sarma, G. R., Immanuel, C., Kailasam, S., Narayana, A. S., &, Venkatesan, P., (1986) Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. The American Review of Respiratory Disease, 133 (6), 1072-1075.
13. Pritchard, A. J., Hayward, A. C., Monk, P. N., &, Neal, K. R., (2003) Risk factors for drug resistant tuberculosis in Leicestershire-poor adherence to treatment remains an important cause of resistance. Epidemiology and Infection, 130 (3), 481-483.
14. Jaggarajamma, K., Sudha, G., Chandrasekaran, V., Nirupa, C., Thomas, A., Santha, T., Muniyandi, M., &, Narayanan, P. R., (2007) Reasons for non-compliance among patients treated under Revised National Tuberculosis Control Programme (RNTCP), Tiruvallur district, south India. Indian Journal of Tuberculosis, 54 (3), 130-135.
15. Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., et al,. & ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine, 174 (8), 935-952.
16. Centers for Disease Control and Prevention (CDC) (2001) Update: fatal and severe liver injuries associated with rifampicin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States 2001. Morbidity and Mortality Weekly Report, 50 (34), 733-735.
17. Joint Tuberculosis Committee of the British Thoracic Society (1998) Chemotherapy and management of tuberculosis in the United Kingdom: recommendations. Thorax, 53 (5), 536-548.
18. R Development Core Team (2004) R: A Language and Environmental for Statistical Computing. Vienna: R Foundation for Statistical Computing.
19. Ormerod, L. P., &, Horsfield, N., (1996) Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tubercle and Lung Disease, 77 (1), 37-42.
20. Tostmann, A., Boeree, M. J., Aarnoutse, R. E., de Lange, W. C., van der Ven, A. J., &, Dekhuijzen, R., (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. Journal of Gastroenterology and Hepatology, 23 (2), 192-202.
21. Tafazoli, S., Mashregi, M., &, O'Brien, P. J., (2008) Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicology and Applied Pharmacology, 229 (1), 94-101.
22. Capelle, P., Dhumeaux, D., Mora, M., Feldmann, G., &, Berthelot, P., (1972) Effect of rifampicin on liver function in man. Gut, 13 (5), 366-371.
23. Ho, C. C., Chen, Y. C., Hu, F. C., Yu, C. J., Yang, P. C., &, Luh, K. T., (2009) Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clinical Infectious Diseases, 48 (11), 1526-1533.
24. Saigal, S., Agarwal, S. R., Nandeesh, H. P., &, Sarin, S. K., (2001) Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. Journal of Gastroenterology and Hepatology, 16 (9), 1028-1032.
25. Szklo, A., Mello, F. C., Guerra, R. L., Dorman, S. E., Muzy-de-Souza, G. R., &, Conde, M. B., (2007) Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury. International Journal of Tuberculosis and Lung Disease, 11 (7), 775-780.
26. Ziganshina, L. E., &, Squire, S. B., (2008) Fluoroquinolones for treating tuberculosis. Cochrane Database of Systematic Reviews, 23 (1), CD004795.
27. Sharma, S. K., Singla, R., Sarda, P., Mohan, A., Makharia, G., Jayaswal, A., Sreenivas, V., &, Singh, S., (2010) Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clinical Infectious Diseases, 50 (6), 833-839.
28. Hinderaker, S. G., Ysykeeva, J., Veen, J., &, Enarson, D. A., (2009) Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan. International Journal of Tuberculosis and Lung Disease, 13 (12), 1560-1562.